<p><strong>Pediatric Use</strong>: This tablet is not authorized for use in pediatric patients younger than 12 years of age or weighing less than 40 kg. The safety and effectiveness of this tablet have not been established in pediatric patients.<br />
<br />
<strong>Geriatric Use</strong>: Clinical studies of this tablet include subjects 65 years of age and older and their data contributes to the overall assessment of safety and efficacy.<br />
<br />
<strong>Renal Impairment</strong>: No dosage adjustment is needed in patients with mild renal impairment. In patients with moderate renal impairment (eGFR &gt;30 to &lt;60 mL/min), reduce the dose of This tablet to 150 mg Nirmatrelvir and 100 mg Ritonavir twice daily for 5 days. This tablet is not recommended in patients with severe renal impairment (eGFR &lt;30 mL/min).<br />
<br />
<strong>Hepatic Impairment</strong>: No dosage adjustment of this tablet is needed for patients with either mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. This tablet is not recommended in patients with severe hepatic impairment (Child-Pugh Class C).</p>